RESUMO
Pancreatic neuroendocrine tumors (pNET) are a rare malignancy. Many patients will present with metastatic disease most commonly to the liver. Currently the standard of care for treatment of liver metastases from neuroendocrine tumors (NETs) is surgical resection. However, only few patients are candidates for surgical resection and require alternative options. Given the rarity of this disease; data regarding treatment options are minimal. In this paper, we will review data presented at the annual meeting of ASCO 2014 about the Survival following Y90 radioembolization for neuroendocrine tumor liver metastases (Abstract #e15166). This abstract shows evidence for survival benefit with the use of radioembolization in the treatment of metastatic neuroendocrine tumors to the liver.
Assuntos
Quimioembolização Terapêutica/métodos , Neoplasias Hepáticas/terapia , Tumores Neuroendócrinos/terapia , Neoplasias Pancreáticas/terapia , Radioisótopos de Ítrio/uso terapêutico , Humanos , Neoplasias Hepáticas/secundário , Tumores Neuroendócrinos/patologia , Neoplasias Pancreáticas/patologia , Compostos Radiofarmacêuticos/uso terapêutico , Dosagem Radioterapêutica , Análise de Sobrevida , Resultado do TratamentoRESUMO
Ampullary carcinomas are rare malignancies representing less than 1% of all gastrointestinal cancers. Given the low incidence rate, there is scarcity of data regarding the survival benefit of the treatment options available. In the 2014 ASCO Gastrointestinal Cancers Symposium there were two abstracts that discussed the role of pancreaticoduodenectomy and adjuvant radiation therapy in ampullary carcinoma. The first study (Abstract #366) demonstrated a decline in morbidity and mortality over time for pancreaticoduodenectomy making it a reasonable option for successful treatment of ampullary carcinoma. The second study (Abstract #282) showed that adjuvant radiation therapy in patients with T2 tumors had improved median survival times compared to patients that did not receive radiation therapy.